Krystal Biotech, Inc.
KRYS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $5 | $4 | $5 | $5 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $5 | $4 | $5 | $4 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1.8% | 8.9% | -3.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94.2% | 92.5% | 94.3% | 94.6% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 50.7% | 42.5% | 42.9% | 47.1% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 81.2% | 39.9% | 40.5% | 49.9% |
| EPS Diluted | 2.66 | 1.29 | 1.2 | 1.52 |
| % Growth | 106.2% | 7.5% | -21.1% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |